Enzolytics

ENZC · OTC

$0.0004−$0.0001 (−20.00%)TodayMarket closed · Oct 20, 3:53 PM ET

Prev close $0.0005

About ENZC

Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company is headquartered in Plano, Texas. The company went IPO on 2008-12-29. The firm is focused on commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products. Its subsidiaries include BioClonetics lmmunotherapy, Inc. and Biogenysis, Inc.

Employees: 0
Headquarters: Plano, Texas
Listed: Dec 29, 2008
Sector: Health Care
Industry: Biotechnology
Website: enzolytics.com

ENZC key statistics

Market cap: 1.93M
Price-earnings ratio: 0.00
Dividend yield: —
Average volume: 4.18M
Volume: 4.51M
Open price: $0.0004
High today: $0.0005
Low today: $0.0004
52 Week high: $0.0013
52 Week low: $0.0002

Enzolytics (ENZC) at a glance

As of Oct 20, 2026, Enzolytics (ENZC) shares are priced at $0.0004, giving the company a market cap of 1.93M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0004 and $0.0005. The current price is 0.0% above the day's low and 20.0% below its high.

Volume so far is 4.51M shares, in line with the average of 4.18M shares a day.

Over the past year Enzolytics has ranged from $0.0002 to $0.0013, and now sits 18% of the way up that range.

ENZC news

Press releaseACCESSWIREJul 26, 11:00 AM ET
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release

Similar companies

Companies in the same industry as Enzolytics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.